Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEXUS study of necitumumab with carboplatin + nab-paclitaxel + pembrolizumab in untreated advanced squamous NSCLC
jRCT2031210387Phase 2Active, not recruiting
- Sponsor
- Nippon Kayaku Co., Ltd.
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of necitumumab in Pulmonary squamous cell carcinoma (4 arms), sponsored by Nippon Kayaku Co., Ltd. Primary endpoints: Maximum tolerated dose, Dose-limiting toxicity and 2 more. Started Aug 2022; status: active, not recruiting.
02
Drugs
necitumumab
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on jRCT2031210387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210387.